首页 › 肾癌(肾细胞癌) › 亚利桑那州 › Tucson
Tucson AZ 肾癌(肾细胞癌)临床试验
7项针对 肾癌(肾细胞癌)的研究正在 Tucson及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
招募中1 期
- University of Arizona Cancer Center, Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #1, Tucson
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
招募中3 期
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
招募中1/2 期
- University of Arizona, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
招募中1 期
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
招募中3 期
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
其他城市的 肾癌(肾细胞癌)试验
- Houston, TX35 项研究
- New York City, NY27 项研究
- Dallas, TX23 项研究
- Nashville, TN23 项研究
- St. Louis, MO23 项研究
- Los Angeles, CA20 项研究
- Boston, MA16 项研究
- Baldwin Park, CA16 项研究
- Pittsburgh, PA15 项研究
- Philadelphia, PA15 项研究
- Queens, NY15 项研究
- Jacksonville, FL14 项研究
Tucson的其他研究
- 乳腺癌20 项研究
- 肥胖症18 项研究
- 非小细胞肺癌17 项研究
- 超重15 项研究
- 转移性癌症14 项研究
- 癌症(所有类型)12 项研究
- 心血管疾病12 项研究
- 结直肠癌11 项研究
- 前列腺癌11 项研究
- 2型糖尿病11 项研究
- 脂肪性肝病10 项研究
- 心力衰竭10 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。